NL-OMON55829已完成3 期
A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson*s disease - M15-741
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Adult male or female subjects, 30 years of age or older at the time of
- •screening, with a diagnosis of idiopathic PD that is levodopa-responsive
排除标准
- •Subjects judged by the investigator to be adequately controlled by current
- •therapy, that don't have recognizable/identifiable Off and On states (motor
- •fluctuations), and have less than 2.5 hours of Off time per day.
研究者
相似试验
进行中（未招募）
1 期
Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion studyParkinson's DiseaseEUCTR2018-002144-85-NLAbbVie Deutschland130
进行中（未招募）
1 期
Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion studyMedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersParkinson's DiseaseEUCTR2018-002144-85-DEAbbVie Deutschland240
进行中（未招募）
1 期
Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion studyMedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersParkinson's DiseaseEUCTR2018-002144-85-BEAbbVie Deutschland240
进行中（未招募）
1 期
Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion studyParkinson's DiseaseEUCTR2018-002144-85-DKAbbVie Deutschland240
进行中（未招募）
1 期
Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion studyMedDRA version: 21.1Level: PTClassification code 10068100Term: Vascular parkinsonismSystem Organ Class: 10029205 - Nervous system disordersParkinson's DiseaseEUCTR2018-002144-85-ITABBVIE DEUTSCHLAND GMBH & CO. KG130